跳到正文
原文
bioRxiv 预印本· Dey, A., Smith, N., Tirard, A., Arnold, B., Chan, T., Lombardi-Story, J., Casson, T., Behnan, T. T., Aguilar-Fernandez, S., Fathi, A. T., Hobbs, G. S., Hock, H., Amrein, P. C., Reeves, P., Jan, M., Bod, L., Graubert, T. A., Brunner, A. M., Narayan, R., Villani, A.-C. ·· 13 天前AI 评分38

阿扎胞苷联合TIM-3抑制剂sabatolimab治疗MDS和CMML的应答与独特免疫及抗原呈递状态相关

Response to azacitidine and the TIM-3 inhibitor, sabatolimab, in MDS and CMML is associated with distinct immune and antigen-presentation states

AI 导读

单细胞RNA测序分析显示,阿扎胞苷联合TIM-3单抗sabatolimab治疗MDS和CMML时,应答者在基线具有较高的HLA II类表达及独特的CD8 T细胞群和干扰素应答程序。治疗应答伴随骨髓CD8/CD4 T细胞收缩及GZMH/IFITM1表达细胞毒性CD8 T细胞扩增。TIM-3主要表达于树突状细胞和NK细胞。

来源:bioRxiv 预印本 · biorxiv.org